Screener
Haemonetics HAE Apheresis — Cost of goods sold
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
|---|---|---|
| Total net revenues | $339,380 | $321,394 |
| Significant segment expenses and operating performance: | ||
| Apheresis | ||
| Cost of goods sold | $84,131 | $75,865 |
| Selling, general and administrative | 44,264 | 39,880 |
| Research and development | 6,378 | 6,816 |
| Apheresis operating income | $56,545 | $59,175 |
| MedSurg |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's apheresis — cost of goods sold?
- Haemonetics (HAE) reported apheresis — cost of goods sold of $84.13M in Q2 2026.
- What does apheresis — cost of goods sold mean?
- This metric includes the direct costs associated with producing and delivering the products and services sold within the Apheresis segment, such as raw materials, direct labor, and manufacturing overhead. It is a critical measure of the segment's production efficiency and gross margin potential. Changes in this figure relative to revenue can signal shifts in manufacturing costs or pricing power.
Ask your AI about Haemonetics's apheresis — cost of goods sold.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude